The last 24 hours offered an important lesson over just how closely analysts and investors are tracking every movement on the immunotherapy front in cancer R&D.
Biodesix scored itself a CE mark that will help expand access to its personalized lung cancer treatment test, a big milestone in the Colorado outfit's push to bring the product into more widespread use.
Back in 2010, Ariad Pharmaceuticals' ridaforolimus was a promising cancer therapy worth up to $700 million in the eyes of Merck. Now, in light of an FDA rejection and some dimming development prospects, Merck has quietly washed its hands of the drug, handing it back to its former partner.
A Johns Hopkins team believes that cell-free circulating tumor DNA can serve as a noninvasive biomarker to help determine a number of things about cancer in the body and aid in its treatment.
Scientists continue to push for the development of a more precise, sensitive and cleaner colorectal cancer diagnostic. Now a research team has determined that a simple, at-home test already on the market is highly accurate.
A protein known to be part of a complex communications network within the cell has also been found to be associated with important processes involved in cancer and diabetes.
Myriad Genetics and rival Gene By Gene put to rest their patent infringement fight over BRCA gene testing, though Myriad is continuing to battle other competitors over the same issue.
Exact Sciences goes before an FDA panel of experts on March 27 to argue for approval of its new stool-based colorectal cancer diagnostic. But it may not be an easy sell.
Florida's NeoGenomics has rolled out a number of new diagnostic tests that profile 22 different categories of cancer, including brain, lung, breast, cervix, colorectal, stomach, ovary, soft tissue, thyroid and various types of leukemia tumors.
Belgium's MDxHealth has partnered with generics maker Teva Pharmaceuticals to commercialize its ConfirmMDx for prostate cancer and PredictMDx for glioblastoma tests in Israel.